Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionPrudential Plc
Latest Disclosed Ownership4,036 shares
Latest Disclosed Value $ 531,703
Prudential Plc reports 2.37% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 14, 2026 - Prudential Plc filed a 13F-HR form disclosing ownership of 4,036 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $531,703 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 4,134 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -2.37% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,036 -98 -2.37 532 -9.39 0.0023
2026-02-11 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,134 98 2.43 586 3.53 0.0046
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,036 0 0.00 567 11.64 0.0042
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,036 4,036 507 0.0031
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -21,119 -100.00 0 -100.00
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,119 5,586 35.96 2,433 13.80 0.0122
2024-08-07 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,533 -2,884 -15.66 2,138 -15.83 0.0144
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,417 -1,514 -7.60 2,540 -3.27 0.0194
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,931 -606 -2.95 2,626 13.68 0.0266
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,537 -209 -1.01 2,310 18.10 0.0257
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,746 10,591 104.29 1,956 90.46 0.0229
2023-05-12 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,155 4,257 72.18 1,028 45.88 0.0121
2023-02-09 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,898 3,628 159.82 704 192.12 0.0088
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,270 2,270 241 0.0038
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.